
Cizzle Bio Validates CIZ1B Blood Test for Early Lung Cancer Detection
Dallas-based Cizzle Bio has completed laboratory validation of its CIZ1B biomarker blood test at OmniHealth Diagnostics, marking a shift toward commercial availability for U.S. healthcare providers. The ELISA-based immunoassay is designed to detect protein variants associated with early-stage lung cancer using a small blood sample.
























